The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases and small cell lung cancer (SCLC) representing a highly aggressive neuroendocrine subtype with a poor prognosis. Tumor cells evade immune surveillance by co-opting immune checkpoint pathways, principally programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This review evaluates the mechanisms and therapeutic potential of PD-1 and CTLA-4 blockade in overcoming immune evasion in lung cancer. A structured narrative literature review synthesized evidence from preclinical studies, landmark clinical trials including KEYNOTE-001 and IMpower133, biomarker investigations, and mechanistic research on PD-1/PD-L1 and CTLA-4 pathways in NSCLC and SCLC. PD-1 suppresses effector T-cell activity and enhances regulatory T-cell function within the tumor microenvironment, while CTLA-4 attenuates T-cell priming through competitive B7 ligand binding. Immune escape is further mediated by HLA class I downregulation, impaired antigen presentation, immunosuppressive cytokine signaling, and tumor-infiltrating regulatory T cells. ICI monotherapy significantly improves overall survival in NSCLC with PD-L1 expression ≥50% compared with platinum-based chemotherapy. First-line atezolizumab plus chemotherapy extended median overall survival to 12.3 months, compared with 10.3 months in extensive-stage SCLC. Dual PD-1/CTLA-4 blockade produces synergistic antitumor responses; however, 70–85% of NSCLC patients develop primary or acquired resistance. PD-1 and CTLA-4 blockade has transformed the therapeutic landscape of lung cancer, yet resistance mechanisms, immune-related adverse events, and the absence of validated predictive biomarkers remain critical challenges. Future research must prioritize combination strategies, novel checkpoint targets, and multifactorial biomarker panels to broaden clinical benefit.
Full Text:
PDFReferences
Zhu M, Huang Y, Bender ME, Girard L, Kollipara R, Eglenen-Polat B, Naito Y, Savage TK, Huffman KE, Koyama S, Kumanogoh A, Minna JD, Johnson JE, Akbay EA. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. Cancer Research. 2021;81(7):1813–1826. http://dx.doi.org/10.1158/0008-5472.can-20-2808
Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, Li X, Dong S, Dong Z, Hu S. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduction and Targeted Therapy. 2025;10(1): . http://dx.doi.org/10.1038/s41392-025-02243-6
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicoló E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research. 2021;27(15):4311–4324. http://dx.doi.org/10.1158/1078-0432.ccr-21-0136
Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opinion on Biological Therapy. 2019;20(1):23–33. http://dx.doi.org/10.1080/14712598.2020.1688298
Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V, Ji C. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLOS ONE. 2019;14(5):e0217276. http://dx.doi.org/10.1371/journal.pone.0217276
Roy D, Gilmour C, Patnaik S, Wang LL. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors. Frontiers in Immunology. 2023;14:1264327. http://dx.doi.org/10.3389/fimmu.2023.1264327
Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology. 2022;12:799455. http://dx.doi.org/10.3389/fimmu.2021.799455
Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D, Ge T, He G, Li W, Zhang G, Liu A, Xia Y, Liu Y, Yu J. PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review). Oncology Letters. 2024;28(6):567. http://dx.doi.org/10.3892/ol.2024.14700
Huang R-Y, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology. 2016;6(1):e1249561. http://dx.doi.org/10.1080/2162402x.2016.1249561
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim S-W, Morgensztern D, Johnson ML, Cousin S, Kim D-W, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature Medicine. 2024;30(3):716–729. http://dx.doi.org/10.1038/s41591-024-02808-y
Aden D, Zaheer S, Sureka N, Trisal M, Chaurasia JK, Zaheer S. Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond. Pathology - Research and Practice. 2025;269:155864. http://dx.doi.org/10.1016/j.prp.2025.155864
Lee JB, Kim HR, Ha S-J. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network. 2022;22(1):e2. http://dx.doi.org/10.4110/in.2022.22.e2
Konen JM, Wu H, Gibbons DL. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities. Trends in Pharmacological Sciences. 2024;45(6):520–536. http://dx.doi.org/10.1016/j.tips.2024.04.006
Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology. 2024;17(1):54. http://dx.doi.org/10.1186/s13045-024-01581-2
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2021;2021(4):CD013257. http://dx.doi.org/10.1002/14651858.cd013257.pub3
Wang H, Niu X, Jin Z, Zhang S, Fan R, Xiao H, Hu SS. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. Journal of Experimental & Clinical Cancer Research. 2025;44(1):250. http://dx.doi.org/10.1186/s13046-025-03519-z
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer. 2023;22(1):40. http://dx.doi.org/10.1186/s12943-023-01740-y
Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction and Targeted Therapy. 2025;10(1):227. http://dx.doi.org/10.1038/s41392-025-02280-1
Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Frontiers in Immunology. 2021;12:636568. http://dx.doi.org/10.3389/fimmu.2021.636568
Perea F, Bernal M, Sánchez‐Palencia A, Carretero J, Torres C, Bayarri C, Gómez‐Morales M, Garrido F, Ruiz‐Cabello F. The absence of HLA class I expression in non‐small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. International Journal of Cancer. 2016;140(4):888–899. http://dx.doi.org/10.1002/ijc.30489
Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar,C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen Q-N, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology. 2019;10:193. http://dx.doi.org/10.3389/fimmu.2019.00193
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy. 2024;9(1):176. http://dx.doi.org/10.1038/s41392-024-01868-3
Wang L, Liang Y, Zhao C, Ma P, Zeng S, Ju D, Zhao M, Yu M, Shi Y. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy. 2025;10(1):345. http://dx.doi.org/10.1038/s41392-025-02326-4
Turnis ME, Andrews LP, Vignali DAA. Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology. 2015;45(7):1892–1905. http://dx.doi.org/10.1002/eji.201344413
Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs. 2025;39(2):215–235. http://dx.doi.org/10.1007/s40259-024-00700-2
Anichini A, Perotti VE, Sgambelluri F, Mortarini R. Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers. 2020;12(12):3605. http://dx.doi.org/10.3390/cancers12123605
Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology & Oncology. 2019;12(1):67. http://dx.doi.org/10.1186/s13045-019-0753-2
Hamilton G, Rath B. Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opinion on Biological Therapy. 2019;19(5):423–432. http://dx.doi.org/10.1080/14712598.2019.1592155
Huang P-W, Chang JW-C. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal 2019;42(5):299–306. http://dx.doi.org/10.1016/j.bj.2019.09.002
Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer,” (ed.), Journal of Experimental Medicine. 2019;216(6):1244–1254. http://dx.doi.org/10.1084/jem.20182395
Shen C-R, Chen Y-S. Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science. Biomedical Journal. 2015;38(1):5. http://dx.doi.org/10.4103/2319-4170.151150
Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Frontiers in Immunology. 2019;10:2965. http://dx.doi.org/10.3389/fimmu.2019.02965
Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Frontiers in Immunology. 2023;14:1197364. http://dx.doi.org/10.3389/fimmu.2023.1197364
Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine. 2015;13(1):211. http://dx.doi.org/10.1186/s12916-015-0455-8
Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling. 2022;20(1):44. http://dx.doi.org/10.1186/s12964-022-00854-y
Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB, Rubin EH. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology. 2017;28(6):1388–1398. http://dx.doi.org/10.1093/annonc/mdx076
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer. 2024;23(1):108. http://dx.doi.org/10.1186/s12943-024-02023-w
Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, Wang X. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology. 2019;10:2298. http://dx.doi.org/10.3389/fimmu.2019.02298
Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng W-J, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research. 2021;40(1):184. http://dx.doi.org/10.1186/s13046-021-01987-7
Lee J, Kim EH. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Frontiers in Oncology. 2023;13:123337. http://dx.doi.org/10.3389/fonc.2023.1233376
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong K-K, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. 2016;7(1):10501. http://dx.doi.org/10.1038/ncomms10501
Wei SC, Anang N-AAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe’er D, Allison JP. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences. 2019;116(45):22699–22709. http://dx.doi.org/10.1073/pnas.1821218116
Sánchez-Magraner L, Gumuzio J, Miles J, Quimi N, Martínez del Prado P, Abad-Villar MT, Pikabea F, Ortega L, Etxezarraga C, Martín-Algarra S, Lozano MD, Saiz-Camin M, Egurrola-Izquierdo M, Barredo-Santamaría I, Saiz-López A, Gomez-Mediavilla J, Segues-Merino N, Juaristi-Abaunz MA, Urruticoechea A, Geraedts EJ, van Elst K, Claessens NJM, Italiano A, Applebee CJ, del Castillo S, Evans C, Aguirre F, Parker PJ, Calleja V. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2023;41(14):2561–2570. http://dx.doi.org/10.1200/jco.22.01748
Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Molecular Cancer. 2025;24(1):246. http://dx.doi.org/10.1186/s12943-025-02400-z
He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Research. 2020;30(8):660–669. http://dx.doi.org/10.1038/s41422-020-0343-4
Luo J, Cheng K, Ji X, Gao C, Zhu R, Chen J, Xue W, Huang Q, Xu Q. Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer. Cancer Letters. 2024;591:216892. http://dx.doi.org/10.1016/j.canlet.2024.216892
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental & Molecular Medicine. 2018;50(12):1–11. http://dx.doi.org/10.1038/s12276-018-0191-1
Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, Sun N, He J. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biology and Medicine. 2020;17(3):768–781. http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0121
Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, Araki M, Togashi Y. Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity. Cancer Science. 2023;114(5)1859–1870. http://dx.doi.org/10.1111/cas.15756
Paulsen E-E, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund L-T, Bremnes RM, Donnem T. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy. 2017;66(11):1449–1461. http://dx.doi.org/10.1007/s00262-017-2039-2
Vackova J, Polakova I, Johari SD, Smahel M. CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade. Cancers. 2021;13(8):1935. http://dx.doi.org/10.3390/cancers13081935
Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong K-K, Wolchok JD. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports. 2019;27(3):806–819.e5. http://dx.doi.org/10.1016/j.celrep.2019.03.066
Poon E, Mullins S, Watkins A, Williams GS, Koopmann J-O, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, Wilkinson RW. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. Journal for ImmunoTherapy of Cancer. 2017;5(1):63. http://dx.doi.org/10.1186/s40425-017-0268-8
Reeves KM, Song PN, Angermeier A, Manna DD, Li Y, Wang J, Yang ES, Sorace AG, Larimer BM. 18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition. Clinical Cancer Research. 2021;28(2):327–337. http://dx.doi.org/10.1158/1078-0432.ccr-21-2394
Lisi L, Lacal PM, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research. 2022;175:105997. http://dx.doi.org/10.1016/j.phrs.2021.105997
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(23):2220–2229. http://dx.doi.org/10.1056/nejmoa1809064
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 201533(18):2004–2012. http://dx.doi.org/10.1200/jco.2014.58.3708
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular Cancer. 2022;21(1):28. http://dx.doi.org/10.1186/s12943-021-01489-2
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental & Clinical Cancer Research. 2019;38(1):255. http://dx.doi.org/10.1186/s13046-019-1259-z
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A 2015, “Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2019;372(26):2521–2532. http://dx.doi.org/10.1056/nejmoa1503093
Chang L-S, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews. 2018;40(1):17–65. http://dx.doi.org/10.1210/er.2018-00006
DOI: https://doi.org/10.33846/hd30702
Refbacks
- There are currently no refbacks.
____________________________________________________________________________________________________________________________________________
Health Dynamics || Open Access Journal || Online version only || Publisher: Knowledge Dynamics || ISSN: 3006-5518 (online) || Contact: healthdynamics.journal@gmail.com; +8801814901991; +6282136364408